66
Participants
Start Date
March 31, 2006
Primary Completion Date
April 30, 2009
Study Completion Date
February 29, 2012
5-Fluorouracil
"Combined Modality Treatment:~fluorouracil 225mg/m2 IV continuous infusion days 1-42~Systemic Treatment:~5-fluorouracil 400 mg/m2 bolus 5-fluorouracil 2400 mg/m2 over 46 hours days 1 and 15"
Bevacizumab
"Combined Modality Treatment:~bevacizumab 5mg/kg IV infusion days 1, 15, and 29~Systemic Treatment:~bevacizumab 5 mg/kg days 1 and 15"
Radiation Therapy
radiation 1.8 Gy/day or 28 fractions weeks 1-6
Oxaliplatin
"Systemic Treatment:~oxaliplatin 85 mg/m2 days 1 and 15"
Leucovorin
"Systemic Treatment:~leucovorin 350 mg prior to FU on days 1 and 15"
Consultants in Medical Oncology and Hematology, Drexel Hill
Peninsula Cancer Institute, Newport News
Spartanburg Regional Medical Center, Spartanburg
Wellstar Cancer Research, Marietta
Northeast Georgia Medical Center, Gainesville
Integrated Community Oncology Network, Jacksonville
Watson Clinic Center for Cancer Care and Research, Lakeland
Florida Cancer Specialists, Fort Myers
Northeast Alabama Regional Medical Center, Anniston
Tennessee Oncology, Nashville
Chattanooga Oncology Hematology Associates, Chattanooga
Consultants in Blood Disorders and Cancer, Louisville
Northeast Arkansas Clinic, Jonesboro
South Texas Oncology and Hematology, San Antonio
Collaborators (1)
Genentech, Inc.
INDUSTRY
SCRI Development Innovations, LLC
OTHER